Does Riluzole reduce the incidence of chemotherapy-induced nerve injury in patients with colorectal cancer?
NEU-HORIZONS: The neuroprotection and therapeutic use of riluzole for the prevention of oxaliplatin neurotoxicity in patients with colorectal cancer
Prince of Wales Hospital/South Eastern Sydney Local Health Network
100 participants
Jul 4, 2011
Interventional
Conditions
Summary
This study aims to determine whether a drug called Riluzole can prevent chemotherapy-induced nerve injury in patients with colorectal cancer. Who is it for? You can join this study if you are aged 18-80 years and are scheduled to undergo chemotherapy with the drug, oxaliplatin, for the treatment of colorectal cancer. Trial details In this study, participants are randomly (by chance) divided into two groups. One group will take the study drug, Riluzole, at a dose of 50 mg oral tablet twice daily for the duration of chemotherapy treatment (4-6 months), and for 2 weeks following treatment cessation. The other group will receive a placebo (sham) treatment consisting of lactose tablets. During the trial, participants will not know whether they are receiving the active drug or placebo. Participants will be assessed at regular intervals over 2 years to assess their nerve function, quality of life, and cancer-related outcomes.
Eligibility
Inclusion Criteria4
- Receiving oxaliplatin chemotherapy.
- 18-80 years of age.
- Able to provide written informed consent.
- Histological or cytological confirmation of colorectal cancer.
Exclusion Criteria8
- Baseline clinical and nerve conduction evidence of pre-existing neuropathy.
- Past history of neurotoxic chemotherapy treatment.
- Concurrent use of anticonvulsant medications that modulate axonal Na+ conductances (carbamazepine, topiramate, phenytoin).
- Evidence of baseline elevation of hepatic transaminases (greater than 3 times the upper limit of normal) on liver function testing.
- Administration of another investigational drug within 30 days prior to randomisation.
- A history of severe hypersensitivity reactions to riluzole or any of the tablet components
- Significant neurological or psychiatric disorders.
- Pregnancy or lactation. Contraception is required in pre-menopausal female patients.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Patients receiving oxaliplatin chemotherapy for colorectal cancer will be randomised into either the study drug arm or placebo control arm. Participants will be started on either riluzole 50 mg oral tablet twice daily or the twice daily lactose placebo tablet. Following randomisation, therapy will be continued for the duration of oxaliplatin treatment (4-6 months) and for 2 weeks following treatment cessation.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12611000514909